A Note by Carson Poupore
Download the full Note here.
With 42.4 percent of United States adults suffering from clinical obesity and 9.2 percent of adults suffering from it severely, the following archetypical story is far too familiar in recent years. Seeking dietary control and weight loss, a patient consults their physician. The physician, comporting with their standard of care, prescribes Ozempic, which is popularly understood to resolve the patient’s issue. Based on information communicated by Novo Nordisk, Ozempic’s manufacturer, the physician fully informs their patient of Ozempic’s side effect risks. The patient starts the prescription and feels a newfound sense of hopeful control. But this feeling is short-lived. Soon after, the patient constantly feels nauseous, vomits after eating, and suffers from abdominal pain. The patient never expected this. After correlating these unforeseen symptoms with Ozempic prescription, the patient concludes that they would never have taken … Read the rest